EX-99.1 2 dex991.htm PRESS RELEASE PRESS RELEASE

Exhibit 99.1

I-many Press Release

 

I-many Reports Fourth Quarter and Year-End 2005 Financial Results

 

Highlights:

 

Q4 net revenue $8.9 million, up 26% from Q3

 

Q4 2005 deferred revenue and unamortized subscriptions up 62% vs. Q4 2004

 

Q4 license revenue up 373% to $2.7 million from Q3

 

Gross value of license contracts signed up 13% in 2005 vs. 2004

 

Unamortized subscriptions reached $8.6 million, up 325% at end of 2005 vs. 2004

 

 

EDISON, N.J.—January 31, 2006—I-many, Inc. (NASDAQ:IMNY), the leading provider of advanced Enterprise Contract Management (ECM) solutions for managing corporate commitments, reported financial results for the fourth quarter and year-end 2005.

 

Net revenues for the fourth quarter 2005 totaled $8.9 million, an increase of 26% from $7.1 million reported in the previous quarter, and a decrease of 7% from $9.5 million reported in the fourth quarter of 2004. Net loss for the fourth quarter of 2005 narrowed to $(0.03) per share, from a loss of $(0.07) per share in the previous quarter and $(0.05) per share in the fourth quarter of 2004.

 

Quarter-end cash, restricted cash and short-term investments was $17.4 million, as compared to $18.2 million at end of the previous quarter.

 

For the year ended December 31, 2005, net revenues totaled $33.2 million, a decrease of 13% from $38.4 million reported in the previous year. Net loss for 2005 was $(0.19) per share, versus a loss of $(0.18) per share in 2004.

 

Net revenues exclude the portion of the gross value of license and service contracts booked during the year that the company cannot realize until future periods. The gross value of license contracts signed during the year increased from $11.5 million in 2004 to $13.1 million in 2005, a gain of 13%.

 

The value of unamortized subscriptions to be recognized over the next five years totaled $8.6 million at the end of the fourth quarter 2005, an increase of 8% from $7.9 million for the previous quarter, and up 325% from $2.0 million at end of the fourth quarter 2004. Revenue from contracted professional services to be provided in future periods totaled $4.1 million at the end of the fourth quarter 2005, up 28% from $3.2 million for the previous quarter. The total amount of deferred revenue and unamortized subscriptions was $19.4 million at the end of the fourth quarter 2005, an increase of 11% from $17.5 million for the previous quarter, and up 62% from $12.0 million at the end of the fourth quarter 2004.

 

License revenue for the fourth quarter of 2005 totaled $2.7 million, an increase of 373% from $567,000 in the previous quarter, and was down 9% from $2.9 million for the same period in 2004. Service revenue of $6.2 million decreased 4% from $6.5 million the previous quarter, and decreased 6% from $6.6 million for the same year-ago period.

 

For the full year of 2005, license revenue of $6.8 million decreased 40% from $11.3 million in 2004. Service revenue of $26.4 million in 2005 decreased 3% from $27.1 million reported in 2004.


These results are in-line with I-many’s guidance provided on its October 26, 2005 conference call.

 

“I-many maintained its industry leadership position in 2005, while also undergoing a significant transformation,” notes I-many CEO and president, Yorgen Edholm, “including transitions to new senior management; new corporate governance with active shareholder involvement; and a new, very powerful, software platform. We’ve also seen a dramatic expansion of subscription-based licenses introduced last year.

 

“While some of these changes will take a few quarters to become fully realized, initial benefits can be seen in our product quality, product roadmap, and the substantial increase in sales in the fourth quarter. We have also seen results from our renewed focus and commitment to the Life Science market, where 23 of the top 25 pharmaceutical companies have chosen I-many as their partner. With the completion of the new ECM-F platform, we can now focus on layering upon it new applications. Because of the efficiencies this will provide, it will allow us to align, over time, our R&D expenditures closer to industry averages, and more readily expand to new vertical markets. All together, we are now managing a strong deal and product pipeline that has set I-many on an excellent course for 2006.”

 

I-many CFO Kevin Harris added, “It is also important to recognize the dual impact of our subscription service offering. Externally, it expands our market to customers that find regular subscription payments an easier and more flexible implementation of ECM. Internally, it provides I-many with the potential for smoother, more predictable revenue growth. The effect of our increasing subscription revenue is also important to consider when comparing current results to previous periods when subscriptions were a smaller percentage of sales.”

 

Other significant milestones during the fourth quarter and the year included:

 

    12 license transactions for the quarter (standard and subscription), up from nine during the previous quarter.

 

    37 new license transactions (standard and subscription) for the year.

 

    Three new subscription transactions were signed during the quarter, for a total of 16 for the year and up from five signed in all of 2004.

 

    Three new customers were signed in the fourth quarter, bringing the total to 14 for the year and further expanding the company’s industry-leading customer base. Most notably, nine of the year’s new customers are in vertical markets outside of Life Sciences. This includes three members of the Fortune 200 that were signed during the third and fourth quarters: a world-leading manufacturer and marketer of imaging products; a leading global technology corporation; and one of the largest health benefits companies.

 

2006 Guidance

 

2006 will see the phased release of applications based on I-many’s next generation software platform that unifies different product offerings and provides a common, interoperable foundation. Benefits include faster, more efficient introduction and implementation of new ECM solutions. Management believes this new platform will set the industry standard for contract management solutions for years to come, supporting both licensed solutions and new hosted services.

 

The company plans to strengthen its important base of Life Science customers, and expects to see significant growth in this area as it helps customers meet constantly changing regulatory requirements, like Medicare Part D. I-many also plans to further leverage its success in Life Science by providing ECM to other industries, where new government compliance rules, like Sarbanes-Oxley, and


the drive to reduce cost and increase profits, are increasing the demand for solutions like those offered by I-many.

 

Management anticipates these efforts will drive growth in 2006 in terms of both recognized revenue and total recognized and deferred revenue from new contracts. While it is difficult to predict the mix of recognizable and deferred transactions the company will sign, management expects the gross value of new license transactions in 2006 to be in excess of $14 million. This result could be substantially higher if the company realizes one or more new large customers.

 

Recurring revenue from maintenance and support, hosting and subscription revenue is anticipated to be approximately $16 million in 2006. Total recognized revenues are expected to be the in the range of $38 to $42 million.

 

Management expects GAAP expenses to range from $44 to $46 million, including approximately $2.5 million of non-cash charges, and cash at year end to be between $14 and $16 million.

 

Management is including additional financial information in this press release and in its annual report on Form 10-K that it believes will give shareholders additional insight into quarterly and annual results. Following the balance sheet and income statement, management has included a table that shows the results for the fourth quarter and the full year 2005 compared to the comparable periods in 2004 for new license transactions including subscription contracts, the recognition into reportable revenue of subscriptions and other deferred transactions, and the reconciliation of those numbers to total product revenue according to generally accepted accounting principles (“GAAP”).

 

I-many will hold a conference call tomorrow, Wednesday, February 1st, 2006, at 10:00 a.m. Eastern Time. The call-in number is (866) 202-3048 or (617) 213-8843, passcode 96029238. The call is also being webcast and can be accessed at I-many’s web site at www.imany.com.

 

Use of Non-GAAP Financial Information

 

The company supplements its GAAP financial statements with a non-GAAP quarterly and annual reconciliation of the gross value of license transactions to its reported GAAP product revenues. This non-GAAP financial information is provided as additional information for investors and is not in accordance with or an alternative to GAAP. Management believes its inclusion can enhance an overall understanding of the company’s past operational performance and also its prospects for the future. This reconciliation of product revenues is made with the intent of providing both management and investors a more complete understanding of the revenue performance of the company, as opposed to GAAP revenue results, which do not include the impact of newly-executed subscription agreements and other deferred revenue arrangements that are material to the ongoing performance of the company’s business. This information quantifies the various components comprising current revenue, which in each quarter consists of revenues from licenses sold in current periods plus revenues deferred from prior periods, less revenue deferred from licenses sold in current periods. Management uses this information as a basis for planning and forecasting core business activity in future periods and believes it is useful in understanding our results of operations. The presentation of this additional revenue information is not meant to be considered in isolation or as a substitute for revenues reported in accordance with generally accepted accounting principles in the United States.

 

About I-many

 

I-many (NASDAQ:IMNY) is the leading provider of advanced Enterprise Contract Management solutions for managing corporate commitments. Designed to extend beyond the traditional contract management capabilities, I-many ContractSphere(R) offers an end-to-end solution, from pre-contract processes and contract management to transaction compliance. Ultimately, this provides companies with the visibility and control needed to manage any type of commitment—from contracts and


obligations to payments and collections. The result is increased revenue, minimized risk and dramatically reduced operating costs, which deliver improved profitability with hard return on investment. More than 280 customers across 21 industries worldwide have implemented and realized the value of I-many business solutions. For more information, please visit www.imany.com.

 

This news release contains forward-looking statements, and actual results may vary from those expressed or implied herein. Factors that could affect these results include: the risk of unforeseen technical or practical impediments to planned software development, which could affect the company’s product release timetable; the inherent risks of large software implementation projects, which can cause customer disagreements that could affect I-many’s ability to collect both services and license revenue, whether recognized or deferred; the possibility that customers could cancel maintenance and support services at the time of annual renewal, which could decrease I-many’s base of recurring revenue; the possibility that current economic conditions will not improve as anticipated or will deteriorate; the possibility that extraordinary events outside the company’s control could extend the length of the sales cycle for the company’s products or make the market for the company’s products more unpredictable; the risk that the company’s historical dependence on the healthcare market will continue; the risk that the company will not be successful in opening new markets for its products; and other risk factors set forth from time to time in the company’s filings with the Securities and Exchange Commission.

 

Summary Tables

 

Fourth Quarter Results


   Q4 ‘05

    vs. Q3 ‘05

    % D

    vs. Q4 ‘04

    % D

 

Net Revenues

   $ 8.9 M     $ 7.1 M     +26 %   $ 9.5 M     -7 %

Net loss/Share

   $ (0.03 )   $ (0.07 )         $ (0.05 )      

Cash, Restricted Cash, Short Term Investments

   $ 17.4 M     $ 18.2 M     -4 %   $ 21.5 M     -19 %

Value of Unamortized Subscriptions

   $ 8.6 M     $ 7.9 M     +8 %   $ 2.0 M     +325 %

Deferred Revenue & Unamortized Subscriptions

   $ 19.4 M     $ 17.5 M     +11 %   $ 12.0 M     +62 %

License Revenue

   $ 2.7 M     $ 567,000     +373 %   $ 2.9 M     -9 %

Service Revenue

   $ 6.2 M     $ 6.5 M     -4 %   $ 6.6 M     -6 %

New License Transactions (Traditional & Subscription)

     12       9     +33 %     16     -25 %

New Subscriptions Only

     3       5     -40 %     3     0 %

New Customers

     3       4     -25 %     9     -66 %

 

M=Millions


Year-end Results


   FY 2005

    vs. FY 2004

    % D

 

Net Revenues

   $ 33.2 M     $ 38.4 M     -13 %

Net loss/Share

   $ (0.19 )   $ (0.18 )      

Gross Value of License Contracts

   $ 13.1 M     $ 11.5 M     +13 %

License revenue

   $ 6.8 M     $ 11.3 M     -40 %

Service Revenue

   $ 26.4 M     $ 27.1 M     -3 %

New Subscriptions

     16       5     +220 %

New License Transactions

     37       40     -7 %

 

M=Millions


I-MANY, INC.

Condensed Consolidated Balance Sheets

(in thousands)

 

     December 31,
2005


   December 31,
2004


Assets

             

Current Assets:

             

Cash and cash equivalents

   $ 16,805    $ 6,098

Restricted cash

     —        161

Short-term investments and securities held for sale

     —        14,610

Accounts receivable

     9,577      9,964

Other current assets

     845      518
    

  

Total current assets

     27,227      31,351

Property and equipment, net

     1,188      1,300

Restricted cash

     555      663

Other assets

     122      120

Acquired intangible assets, net

     713      2,097

Goodwill

     8,667      8,667
    

  

Total assets

   $ 38,472    $ 44,198
    

  

Liabilities and Stockholders’ Equity

             

Current liabilities:

             

Accounts payable and accrued expenses

   $ 5,618    $ 6,571

Current portion of deferred revenue

     11,521      9,975

Capital lease obligations

     8      160
    

  

Total current liabilities

     17,147      16,706

Deferred revenue, net of current portion

     1,242      275

Other long-term liabilities

     1,054      1,347

Stockholders’ equity

     19,029      25,870
    

  

Total liabilities and stockholders’ equity

   $ 38,472    $ 44,198
    

  


I-MANY, INC.

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

(Unaudited)

 

     Three months ended
December 31,


    Twelve months ended
December 31,


 
     2005

    2004

    2005

    2004

 

Net Revenues:

                                

Product

   $ 2,680     $ 2,934     $ 6,804     $ 11,275  

Services

     6,219       6,587       26,445       27,138  
    


 


 


 


Total net revenues

     8,899       9,521       33,249       38,413  

Cost of revenues

                                

Product

     226       332       520       832  

Services

     3,399       3,476       14,764       14,733  
    


 


 


 


Total cost of revenues

     3,625       3,808       15,284       15,565  
    


 


 


 


Gross profit

     5,274       5,713       17,965       22,848  
    


 


 


 


Operating expenses:

                                

Sales and marketing

     2,449       2,685       8,626       9,020  

Research and development

     2,540       2,995       11,267       11,874  

General and administrative

     1,206       1,631       4,819       5,552  

Depreciation

     205       253       796       917  

Amortization of acquired intangible assets

     343       378       1,384       1,465  

In-process research and development

     —         —         —         290  

Restructuring and other charges (credits)

     15       (25 )     (10 )     1,346  
    


 


 


 


Total operating expenses

     6,758       7,917       26,882       30,464  
    


 


 


 


Loss from operations

     (1,484 )     (2,204 )     (8,917 )     (7,616 )

Other income, net

     103       77       285       244  
    


 


 


 


Loss before income taxes

     (1,381 )     (2,127 )     (8,632 )     (7,372 )

Benefit from income taxes

     0       0       0       (82 )
    


 


 


 


Net loss

   ($ 1,381 )   ($ 2,127 )   ($ 8,632 )   ($ 7,290 )
    


 


 


 


Basic and diluted net loss per common share

   ($ 0.03 )   ($ 0.05 )   ($ 0.19 )   ($ 0.18 )
    


 


 


 


Weighted average shares outstanding

     46,340       42,241       44,548       41,367  
    


 


 


 



I-MANY, INC.

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

(Unaudited)

 

     Three months ended
December 31,


    Twelve months ended
December 31,


 
     2005

    2004

    2005

    2004

 

Net Revenues:

                                

Product

   $ 2,680     $ 2,934     $ 6,804     $ 11,275  

Services

     6,219       6,587       26,445       27,138  
    


 


 


 


Total net revenues

     8,899       9,521       33,249       38,413  

Operating Expenses:

                                

Cost of third party technology

     226       332       520       832  

Cost of services

     3,399       3,476       14,764       14,733  

Sales and marketing

     2,449       2,685       8,626       9,020  

Research and development

     2,540       2,995       11,267       11,874  

General and administrative

     1,206       1,631       4,819       5,552  

Depreciation

     205       253       796       917  

Amortization of acquired intangible assets

     343       378       1,384       1,465  

In-process research and development

     —         —         —         290  

Restructuring and other charges (credits)

     15       (25 )     (10 )     1,346  
    


 


 


 


Total operating expenses

     10,383       11,725       42,166       46,029  
    


 


 


 


Loss from operations

     (1,484 )     (2,204 )     (8,917 )     (7,616 )

Other income, net

     103       77       285       244  
    


 


 


 


Loss before income taxes

     (1,381 )     (2,127 )     (8,632 )     (7,372 )

Benefit from income taxes

     0       0       0       (82 )
    


 


 


 


Net loss

   ($ 1,381 )   ($ 2,127 )   ($ 8,632 )   ($ 7,290 )
    


 


 


 


Basic and diluted net loss per common share

   ($ 0.03 )   ($ 0.05 )   ($ 0.19 )   ($ 0.18 )
    


 


 


 


Weighted average shares outstanding

     46,340       42,241       44,548       41,367  
    


 


 


 


 

Note:  We are transitioning to the income statement format presented on this page. We will no longer use the first format presented in future earnings releases. We are adding additional information (cost of third party technology) and removing the gross profit line. We think this presentation is consistent with the presentation of many other software companies and adds additional information to increase transparency to investors.


Reconciliation of Value of License Transactions to Reportable Product Revenue

 

     Three months ended
December 31,


   Twelve months ended
December 31,


     2005

   2004

   2005

   2004

     (AMOUNTS IN THOUSANDS)

Gross value of license contracts sold:

                           

Health and Life Sciences

   $ 3,599    $ 3,886    $ 10,818    $ 8,477

Industry Solutions

     138      1,617      2,282      3,071
    

  

  

  

       3,737      5,503      13,100      11,548

Add product revenue recorded in current quarter from contracts sold in prior periods:

                           

Health and Life Sciences—subscriptions

     325      69      926      102

Health and Life Sciences—other deferrals

     0      289      1,476      3,428

Industry Solutions—subscriptions

     35      0      35      0

Industry Solutions—other deferrals

     525      0      525      794
    

  

  

  

       885      358      2,962      4,324

Less value of license contracts sold in current quarter and deferred to future periods:

                           

Health and Life Sciences

     1,907      2,802      7,840      3,922

Industry Solutions

     35      125      1,418      675
    

  

  

  

       1,942      2,927      9,258      4,597
    

  

  

  

Product revenue recorded:

                           

Health and Life Sciences

     2,017      1,442      5,380      8,085

Industry Solutions

     663      1,492      1,424      3,190
    

  

  

  

     $ 2,680    $ 2,934    $ 6,804    $ 11,275
    

  

  

  

 

 

CONTACT:

 

I-many, Inc.

Kevin Harris, 732-452-1515

kharris@Imany.com

 

or

 

Investor Relations:

Liolios Group, Inc.

Scott Liolios, 949-574-3860

scott@liolios.com

 

###